In which countries is Belzutifan approved?

Introduction to Belzutifan 

Belzutifan, marketed under the trade name WELIREG™, is an orally administered small molecule that functions as a selective inhibitor of hypoxia‐inducible factor 2α (HIF‐2α). This inhibition of HIF‐2α forms the fundamental mechanism by which belzutifan interferes with pathways integral to tumor progression, as HIF‐2α is critically involved in mediating cellular responses to hypoxic conditions. The specificity of belzutifan for HIF‐2α enables it to target tumors that arise in patients with aberrations in oxygen sensing, most notably in cases related to von Hippel–Lindau (VHL) disease. The comprehensive understanding of its mechanism has emerged from extensive preclinical research and clinical pharmacology studies, which altogether have built confidence in the drug’s ability to modify disease progression in targeted patient populations. 

Therapeutic Indications 

Belzutifan is primarily approved for the treatment of adult patients with von Hippel–Lindau disease who require therapy for associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), and it is under investigation for additional solid tumor indications. Its mechanism of targeting the HIF‐2α pathway is particularly beneficial for conditions driven by hypoxic tumor microenvironments, where the overactivation of HIF transcription factors supports angiogenesis, metabolic reprogramming, and survival of tumor cells. The clinical research supporting these indications has been robust, including early-phase data that thoroughly evaluated its pharmacokinetics and pharmacodynamics in different patient subsets. 

Regulatory Approval Process 

General Drug Approval Procedures 

The regulatory approval process for a new pharmaceutical agent like belzutifan follows a globally harmonized, yet regionally nuanced, pathway. Typically, innovative drugs undergo a comprehensive evaluation of preclinical studies, followed by sequential clinical trials (Phases 1, 2, and 3) to establish safety, efficacy, and an acceptable benefit‐risk profile. Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the National Medical Products Administration (NMPA) in China rigorously review submitted data dossiers that include manufacturing quality specifications, clinical pharmacology, and safety information before granting market authorization. In many cases, especially for treatments addressing high unmet medical needs, expedited approval pathways are available, such as accelerated approvals based on surrogate endpoints or conditional marketing authorizations that allow early access to promising therapies while additional confirmatory trials are ongoing. 

Factors Influencing Approval Decisions 

Approval decisions are influenced by several key factors including the drug’s mechanism of action, clinical efficacy and safety outcomes from pivotal trials, and the overall benefit‐risk balance as determined in the context of the targeted disease. For belzutifan, the demonstrable improvement in progression‐free survival and clinically meaningful responses in patients with VHL disease-associated tumors were particularly influential. Additionally, regulatory agencies factor in the unmet medical need and the robustness of the safety data during both clinical development and post‐approval monitoring strategies. Differences in interpretation of regulatory guidelines between regions can also impact timelines and decision-making processes; for example, some agencies may grant conditional approvals allowing for early use in specialist settings, while others may require additional confirmatory safety data. 

Geographical Approval Status 

Countries with Approval 

Belzutifan has achieved regulatory approval in multiple key regions with distinct approval mechanisms and timelines:

• In the United States, belzutifan received its first approval in August 2021 for the treatment of adult patients with VHL disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors. This approval is based on robust clinical data, where the FDA reviewed comprehensive population pharmacokinetic as well as clinical trial outcomes that underscored its favorable safety and efficacy profile. 

• In the European Union, belzutifan has been granted conditional marketing approvals for specific indications. The EU’s regulatory framework has enabled an expedited, conditional approval for the treatment of both von Hippel–Lindau disease and locally advanced clear cell renal cell carcinoma (ccRCC), with an approval date noted as February 18, 2025. These approvals were granted on the basis of compelling evidence from clinical trials and allowed for early patient access while additional post‐marketing commitments are fulfilled. 

• In China, the National Medical Products Administration (NMPA) has approved belzutifan for use as evidenced by its drug application entry under the number “国药准字HJ20240135,” with the drug trade name WELIREG (维利瑞) being approved on November 15, 2024. This approval reflects the increasing convergence of global clinical data and the localized requirements of Chinese regulatory authorities in accelerating access to innovative treatments. 

• Additionally, within the United Kingdom, specifically in Scotland, the Scottish Medicines Consortium (SMC) has accepted belzutifan for use within NHS Scotland. This acceptance by SMC, as highlighted in reports from MSD Medicine, indicates that belzutifan is available for patients with von Hippel–Lindau disease in Scotland, further expanding its geographical footprint within Europe. The decision in Scotland is particularly notable given the devolved regulatory framework that can lead to earlier access in specialized healthcare settings compared to other regions of the United Kingdom.

These approvals collectively demonstrate that belzutifan is now available in the U.S., across the European Union (with conditional approvals noted for multiple indications), China, and in at least one region of the United Kingdom (Scotland). 

Pending Approvals and Applications 

While belzutifan’s approvals in major regions such as the United States, the European Union, and China are firmly established based on current data, there remain ongoing efforts and submissions in other countries not yet formally approved. Regulatory review processes in several other regions, including parts of Asia outside China, South America, and certain European nations that may apply additional local criteria, are still underway. This means that while approval is evident in core markets, there may be further expansion pending the submission of local clinical data or the completion of additional regulatory requirements. In some instances, access in these regions might initially be provided through compassionate use or expanded access programs pending formal approvals. 

Implications of Approval 

Clinical Implications 

The regulatory acceptance of belzutifan in these key territories has major clinical implications for patients with VHL disease and associated tumors. In the United States, the availability of belzutifan has represented a significant advancement in the therapeutic arsenal for rare, genetic tumor syndromes. The favorable clinical outcomes observed in terms of overall response rate (ORR) and progression‐free survival (PFS) have provided substantial clinical benefit compared with prior therapeutic options. In the European Union, the conditional marketing approval means that patients can access belzutifan sooner in contexts of high unmet need, with continued monitoring to validate long-term efficacy and safety in a real‐world population. Similarly, in China, NMPA approval indicates that patients now have a treatment option that aligns with global standards of care, which is particularly important given the genetic and epidemiological variations observed in different populations. Furthermore, the acceptance in Scotland confirms that national health systems are increasingly supportive of rapid uptake of innovative cancer therapies, ensuring that specialized patient communities benefit from the latest advancements in precision medicine. 

Market and Commercial Implications 

The geographical approval of belzutifan has far-reaching market and commercial implications. From a commercial standpoint, approval in major markets like the United States, European Union, and China opens significant revenue channels, given that these regions collectively represent a vast patient population and robust healthcare reimbursement environments. The conditional approvals in the European Union are particularly important because they often involve commitments from the sponsor to produce further data post-approval, ensuring that belzutifan’s long-term commercial success is grounded in continued clinical research and real-world evidence generation. Approval in Scotland within the United Kingdom not only enhances market penetration in the region but also serves as a case study for further adoption in other parts of the UK and Europe. 

Moreover, the multi-regional approval strategy may reduce the risk of market fragmentation by aligning regulatory standards and facilitating simultaneous launch activities. This harmonization across different jurisdictions can support more coordinated global marketing strategies, streamlined supply chain logistics, and sustainable pricing models that ensure broad patient access while maintaining commercial viability. Additionally, these approvals may stimulate further research collaborations, licensing deals, and potentially mergers and acquisitions within the biopharmaceutical sector, as companies seek to leverage belzutifan’s successful regulatory track record. Commercially, belzutifan serves as an exemplary model of how a well-executed development program can navigate complex regulatory landscapes across geographically diverse markets, thereby establishing a robust global presence. 

Conclusion 

In summary, belzutifan has secured regulatory approval in several critical regions around the globe. In the United States, it is approved and widely available for treating adult patients with von Hippel–Lindau disease-associated tumors, following its approval in August 2021. The European Union has provisionally granted conditional marketing authorization for belzutifan for indications including von Hippel–Lindau disease and locally advanced clear cell renal cell carcinoma, effective from February 18, 2025. In China, the National Medical Products Administration approved the drug for use under the trade name WELIREG (维利瑞) on November 15, 2024, reflecting its integration into the Chinese market. Additionally, in Scotland—a part of the United Kingdom with a devolved health system—the Scottish Medicines Consortium has accepted belzutifan for use, further broadening its availability within Europe. 

This multi-layered approval landscape highlights not only the scientific and clinical success of belzutifan but also underscores the evolving nature of regulatory science in facilitating expedited access to innovative therapies in regions with high unmet medical needs. The approvals obtained across these diverse jurisdictions have significant clinical implications, directly benefiting patients with few treatment options while also yielding substantial market and commercial opportunities for the sponsor. With ongoing applications and potential future approvals across other territories, belzutifan is poised to become an even more integral part of the global therapeutic landscape, setting a benchmark for innovative regulatory strategies and patient access pathways. 

In conclusion, through its robust approval in the United States, conditional marketing authorization in the European Union, official endorsement by China’s NMPA, and acceptance in Scotland, belzutifan exemplifies a successful global launch strategy. Its journey reflects the interplay between cutting‐edge science, rigorous clinical validation, and adaptive regulatory processes that together foster an environment where innovative cancer therapies can rapidly transition from development to widespread clinical use, ultimately benefiting a diverse patient population worldwide.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.